Kailera Launches With $400M to Advance China-Developed Obesity Assets
Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million series A for Kailera Therapeutics, the latest obesity biotech to hit the scene.
Kailera Launches With $400M to Advance China-Developed Obesity Assets Read More »
